

GastroPlus[®]


PBPK modeling software... from discovery through development



GastroPlus[®]

GastroPlus is a mechanistically based simulation software package that simulates intravenous, oral, oral cavity, ocular, inhalation, dermal/subcutaneous, and **NEW!** intramuscular absorption, pharmacokinetics, and pharmacodynamics in humans and animals. This smoothly integrated platform combines a user-friendly interface with powerful science to help you make faster and more informed project decisions!

GastroPlus is by far the most commonly used software of its kind. It has been identified as the #1-ranked program for *in vitro - in vivo* extrapolation (IVIVE) and has been the focus of several publications from the FDA!



The GastroPlus simulations include:

FOR DISSOLUTION & ABSORPTION -

- The Advanced Compartmental Absorption and Transit (ACAT™) model only in GastroPlus!
- Physiological gut models for human, dog, rat, mouse, rhesus monkey, cynomolgus monkey, minipig, rabbit and cat fasted or fed conditions defined
- Vast selection of dosage forms: immediate release, delayed release, controlled release (including dispersed systems, gastric-retention, and more)
- pH-dependent solubility and logD models ionization effects on dissolution & absorption considered
- Paracellular absorption estimate paracellular permeability
- Mechanistic effect of bile salts on drug solubility and dissolution
- Enhanced treatment of nanoparticle effects on solubility and dissolution
- Mechanistic models to predict in vivo precipitation
- Options for defining pH-dependent dissolution (Z-factor) and precipitation rates
- \bullet Saturable metabolism and/or influx/efflux transport along the GI tract
- Mechanistic deconvolutions and In Vitro In Vivo correlations (IVIVCs) for various formulations

FOR PHARMACOKINETICS -

- Whole body, physiologically-based pharmacokinetic (PBPK) models defined including pediatrics
- One-, two-, or three-compartment conventional pharmacokinetic model options available
- Transporter-based IVIVE: automated scaling of permeability across all tissues with PBPK
- Saturable metabolism and transport in liver or any PBPK tissues
- Metabolite tracking easily link the formation of metabolites with the metabolism of the parent(s) in a single simulation
- Mechanistic treatment of biliary secretion and enterohepatic circulation
- Mechanistic static and dynamic DDI predictions
- Automated PBPK/PD model selection with industry standard pharmacodynamic models

Simulation Modes Available -


- Population Simulator™ predict likely distributions of PBPK/PD results over different populations
- Parameter Sensitivity Analysis quickly test sensitivity of results to changes in model parameters
- Batch Simulations screen compound libraries for bioavailability & PK exposure in different species

- NEW! PBPK models for antibody-drug conjugates (ADCs)
- NEW! PBPK physiology models for Chinese (pediatric and adults) and hepatic impairment populations
- NEW! Bolus & controlled release models for subcutaneous and intramuscular injections
- Updated! Animal physiology models for non-oral delivery pathways
- Improved! Reporting functions easy export into Excel spreadsheets
- Upgraded! Automated mechanistic deconvolutions and easier virtual BE simulation setup
- Enhanced! More covariate relationships in the Population Simulator
- ... and more!

ADMET Predictor™ Module

CYP metabolism predictions from chemical structure - quickly create full PBPK models in seconds.

The ADMET Predictor[™] Module extends the capability of GastroPlus by enabling you to obtain predictions from structure of all physicochemical, pharmacokinetic, and CYP metabolism kinetic parameters required for GastroPlus PBPK simulations. The module uses the same models as our best-in-class ADMET Predictor software.



Updated! Enhanced pKa model developed in collaboration with Bayer HealthCare - ALL models retrained with greater accuracy!

This module automatically generates predictions for the following properties:

- CYP metabolism kinetics Vmax, Km, and CLint
- P-gp and OATP transporter inhibition models (classification)
- Aqueous solubility vs. pH profile
- Biorelevant solubility (FaSSIF, FeSSIF, and FaSSGF)
- logD vs. pH profile
- Rabbit corneal permeability
- Human volume of distribution

The ADMET Predictor Module has several critical benefits:

- Blood:brain barrier permeation (classification)
- pKa(s)
 - Tendency to supersaturate in water
 - Diffusion coefficient in water
 - Human effective permeability
 - Human plasma protein binding
 - Human blood:plasma concentration ratio
- (1) by loading a library of chemical structures, quickly set up a database for screening fraction absorbed & bioavailability decide which compounds to carry forward into in vivo studies
- (2) use the in silico predictions and Parameter Sensitivity Analysis to guide your in vitro studies
- (3) begin evaluating different formulation strategies to assess the importance of factors like particle size, solubility and dose on absorption

PBPKPlus™ Module

Ranked #1 in *In Vitro-In Vivo* Extrapolation (IVIVE) by Pfizer! (Cole et al., 2nd Asian Pacific Regional ISSX Meeting, May 2008, Shanghai, China)

Only in GastroPlus! Transporter-based IVIVE: automated scaling of permeability across tissues in the PBPK model


The PBPKPlus Module extends GastroPlus to define a "whole body" PK model, consisting of various tissues. You can easily simulate the distribution & elimination of compound throughout the body and track concentrations in any tissue. Tissues can be defined as needed, or default models can be used with a standard set of compartments:

Brain

Lungs

Venous blood

Skin



organs Customize your PBPK model by treating any tissue as either a perfusion-limited or permeability-limited model, and quickly add/delete tissues as needed – <u>all without writing any equations!</u>

The PBPKPlus Module also provides:

Arterial blood

Reproductive

Heart

Muscle

• Generation of physiological model parameters (tissue weights and volumes, composition, perfusion rates, etc...) with our built-in PEAR Physiology™ (Population Estimates for Age-Related Physiology).

Yellow marrow

Red marrow

Kidney

Current physiologies are:

Adipose


Gut

Liver

Spleen

- Human (American, Japanese, and NEW! Chinese, Male or Female, based on age)
- Infant/pediatric groups
- NEW! Hepatic impairment
- Rat
- Dog
- Mouse
- Monkey
- Rabbit
- Minipig

PEAR Physiol New PEAR Physiology odel 🕥 🗆 Expand \ PEAR Input [mL] Perfusion [mL/s] Huma ٠ Male • 12 ature 2 • leight [cm]: Weight [kg]: 10.24 BMI [kg/m^2]: 2 Body Fat: 27.924 CO [mL/s]: lal: 919.051 (% BW: 8.975) ninder. Adpose tissue in infants and young children still has si er content (45.73% in this physiology) so, unlike in adults, the cose tissue does not represent well the % body fat <u>o</u>ĸ Cancel



- Population simulations based on parameter variances in a sample population define your own age range, % male vs. female, and the number of "virtual" subjects you wish to create
- Novel methods for estimating tissue partition coefficients from logD, pKa, plasma protein binding and Rbp only in GastroPlus!
- Physiological model for kidney including glomerular filtration and reabsorption
- Fitting models to in vivo data (plasma/tissue concentrations, amount excreted in urine, etc...)
- Linking of pharmacodynamic effect directly to concentrations in specific tissues
- Mechanistic transport of drug from hepatocytes to bile in liver, modeled either as a linear process or through carrier-mediated transport
- Report-quality plotted output of all time-dependent results in all tissues
- ... and more!

The DDI Module in GastroPlus allows you to predict drug-drug interactions (DDIs) among drugs and metabolites.

The ability to accurately estimate potential DDIs in silico has several benefits for companies:

- Explore possible effects on the pharmacology and toxicology of drugs
- Identify species-specific changes to estimate how a drug behaves in animals vs. humans
- Investigate the safety profile of drugs that are co-administered prior to filing regulatory submissions with agencies around the world


With the DDI Module, calculating either steady-state and/or dynamic DDIs is managed through our easy-to-use interface. We provide a database of standard compounds for which all relevant parameters (including reported inhibition/induction constants and full compartmental PK/PBPK models) are defined. Of course, you may predict DDIs among any compounds by simply entering the required inputs. As with other GastroPlus modules, there is no equation or code writing required.

What are some of the advantages to using the DDI Module?


- NEW! PBPK models for DDI standard compounds: warfarin and simplified itraconazole
- Population Simulator[™] linked with DDI predictions
- Transporter-based drug-drug interactions
- Metabolic and/or transporter induction
- Linked with the industry's #1-ranked dissolution/absorption (ACAT™) model
- Use with either compartmental PK or PBPK models
- Apply competitive and/or time-dependent inhibition kinetics by parent and/or metabolite(s)
- Simulate DDIs for any species

recombinant enzymes (rCYP)

- Account for enzyme expression level differences in various human populations
- Built-in tool to easily calculate the fraction metabolized (fm) from in vitro assays (rCYPs and microsomes are accommodated)



- Incorporate nonlinear gut contributions to DDIs
- Predict the inhibitor effect using simulated concentrations at the site of metabolism (gut, liver, or any PBPK tissue) for dynamic DDI simulations
- Include the effects of multiple substrates on clearance of other substrates metabolized by the same enzyme



Additional Dosage Routes Module

The Additional Dosage Routes Module in GastroPlus extends the program beyond the traditional oral and intravenous administration routes. With this module, you can simulate drug disposition through additional dosing sites – dermal, intraoral (oral cavity), ocular, pulmonary (intranasal and respiratory), and **NEW!** intramuscular. These models were all developed in collaboration with top 5 pharmaceutical companies. The ability to predict concentration profiles in different regions of the skin, mouth, eye, lungs, nose, and muscle can help you:

- Explore various formulation/drug delivery options to achieve desired therapeutic effects
- Identify species-specific changes to estimate how a drug is handled in animals vs. humans

With the Additional Dosage Routes Module, simulating concentrations through these sites is managed through our easy-to-use interface. Mechanistic, physiologically-based models are provided for each tissue, for different species. You can also customize your own physiology by entering available information into the program. These models are linked with either compartmental or physiologically-based pharmacokinetics (PBPK) in GastroPlus, so you may predict your drug's distribution and elimination once it enters into the systemic circulation. As with other GastroPlus modules, <u>there is no equation or code writing required</u>.

Ocular Model (Ocular Compartmental Absorption & Transit (OCAT™) Model

- Nonlinear metabolism or transport in any eye tissue!
- Two-site melanin binding options!
- Convective flow incorporated into the ocular disposition model
- Physiology models (human, rabbit, and NEW! monkey)

The ocular model of the Additional Dosage Routes Module provides dosing as:

- Eye drop (topical solution or suspension) IVT (intravitreal injection)
- Intravitreal or subconjunctival implants

Some of the processes which can be modeled include:

- Nonlinear metabolism or transport in any eye tissue
- Two-site melanin binding options
- Convective flow incorporated into the ocular
 F
 disposition model
- Predefined physiology models (human, rabbit, and NEW! monkey)
- disposition model

Pulmonary (Intranasal/Respiratory) Model (Pulmonary Compartmental Absorption & Transit (PCAT™) Model

- Nonlinear metabolism or transport in any lung tissue!
- Age-dependent scaling of the pulmonary physiology!
- Physiology models (human, rat, NEW! mouse, and NEW! dog)

The pulmonary model provides dosing via the intranasal or respiratory route as an:

- Immediate release solution
- Immediate release powder


The pulmonary model includes the advanced ICRP 66 deposition model (Smith et al., 1999, LUDEP) for calculating deposition fractions in each compartment of both API and carrier particles. Additionally, you may account for the following processes in your simulations:

• Mucociliary transit

6

- Nonlinear metabolism or transport in any lung tissue
- Lymphatic transport & systemic absorption
- Age-dependent scaling of the human physiology

Save Cancel



Dermal/Subcutaneous Model

The Transdermal Compartmental Absorption & Transit (TCAT[™]) model represents the skin as a collection of the following compartments: stratum corneum, viable epidermis, dermis, subcutaneous tissue, sebum, hair lipid, and hair core. The subcutaneous tissue is also considered. The diagram is shown in the figure below.

The model can simulate a variety of transdermal & subcutaneous dosage forms, specified at different places on the body, including:

- liquid formulations (solutions, lotions, suspensions)
- semi-solid formations (gels, creams, lotions, pastes)
- subcutaneous injections (bolus or controlled release)

Some of the processes modeled include:

- vehicle evaporation
- absorption from the vehicle into the various tissue regions
- nonlinear metabolism in any tissue region
- systemic circulation and lymphatic absorption

Measured in vivo data for any dermal tissue can be used to compare with simulation results. All standard GastroPlus features, including the Population Simulator and Parameter Sensitivity Analysis, can be used with the dermal model.

Oral Cavity Delivery Model


The Oral Cavity Compartmental Absorption & Transit (OCCAT^M) model represents the oral cavity (mouth) as a collection of the following compartments: buccal, gingival, palate, top of the tongue, bottom of the tongue, and mouth floor. The diagram is shown in the figure at right.


The model can simulate a variety of dosage forms including:

- sublingual solutions & tablets
- lingual sprays & supralingual tablets
- controlled release buccal patches

Some of the processes modeled include:

- dissolution & precipitation in the saliva
- diffusion through the oral mucosa
- uptake into systemic circulation
- swallowing of unabsorbed drug





Measured *in vivo* data for any oral cavity tissue can be used to compare with simulation results. All standard GastroPlus features, including the Population Simulator and Parameter Sensitivity Analysis, can be used with the oral cavity model.


When linked with the upgraded ADMET Predictor™ Module, predict CYP metabolism pathways & kinetics, and have the Enzyme Table automatically populated with the correct locations and units!

Updated! Enzyme and transporter expression levels across species - including UGTs and SULTs!

Enhanced! Metabolite tracking options!

The Metabolism and Transporter Module is an optional module that extends the capabilities of GastroPlus to include saturable metabolism and carrier-mediated transport into any compartment (gut, liver, and/or any PBPK tissue), along with metabolite tracking. This module calculates Michaelis-Menten rates for gut and liver (or any PBPK tissue) metabolism and for carrier-mediated transport (influx or efflux) based on input values for Vmax and Km. You can provide Vmax and Km values for each enzyme/transporter independently, or you can lump them into a single effective Vmax and Km, depending on your data. The distribution factors on the Physiology tab are automatically loaded for recognized gut enzymes and transporters, and provide the relative amounts of enzymes or transporters in the various ACAT[™] gut model compartments. The Vmax and Km scale factors on the Pharmacokinetics tab are provided to allow fitting nonlinear kinetic models to your data.

The Metabolism and Transporter Module includes a Units Converter for easy transformation of a variety of your in vitro metabolism or transporter kinetic parameters into parameters and units that can be utilized by the GastroPlus model.



The Units Converter window that provides a convenient way of converting *in vitro* measurements to *in vivo* inputs for the GastroPlus model.

_	Enzyme Table									
	Generic	Enzyme	Location	Data Source	Vmax (mg/s) or (mg/s/mg-enz)	Km (mg/L)	Metabolite	Met_Pare		
•	Atomoxetine	1A2	PBPK	Microsomes	0.000356	3.21	NONE	1		
	Atomoxetine	1A2	Liver	Microsomes	0.0615	3.21	NONE	1		
	Atomoxetine	2C19	PBPK	Microsomes	0.00933	21.37	NONE	1		
	Atomoxetine	2C19	Gut	Microsomes	0.42	21.37	NONE	1		
	Atomoxetine	2C19	Liver	Microsomes	0.42	21.37	NONE	1		
	Atomoxetine	2D6	PBPK	Microsomes	0.00105	0.25	NONE	1		
	Atomoxetine	2D6	Gut	Microsomes	0.0267	0.25	NONE	1		
	Atomoxetine	2D6	Liver	Microsomes	0.0267	0.25	NONE	1		
	Atomoxetine	3A4	PBPK	Microsomes	0.000467	32.23	NONE	1		
	Atomoxetine	3A4	Gut	Microsomes	0.17	32.23	NONE	1		
	Atomoxetine	3A4	Liver	Microsomes	0.17	32.23	NONE	1		
*						8				
		•]					<u>,</u>		
1	Delete Save	Cancel	Unit	Converter						
	Delete Save	Cancel	Unit	Converter						

Define multiple metabolic / transport pathways, with enzymes and transporters placed into the tissues or organs of your choice! Also link formation of different metabolics in a single simulation! New article from FDA scientists compare the Mechanistic Absorption deconvolution in GastroPlus vs. traditional methods – conclusion is that GastroPlus provides "greater predictive accuracy" - Mirza et al., Pharm. Res. 2012


IVIVCPlus is an optional add-on module that provides a convenient way to develop a correlation between either *in vitro* release and *in vivo* release or *in vitro* release and absolute bioavailability. The formed correlation can then be used to predict PK profiles for formulations with different *in vitro* release rates.


GastroPlus was the first software program to offer "mechanistic deconvolutions", which deconvolute, or fit, the *in vivo* dissolution vs. time along the gut lumen. An advantage to using the mechanistic deconvolution method is that it can be linked to a PBPK model. We are pleased to validate the mechanistic deconvolution method through a 5-year Research Collaboration Agreement with the U.S. FDA.

IVIVCPlus offers five methods for deconvolution:

- 1) Mechanistic Absorption Model (GastroPlus)
- 2) Numerical Deconvolution
- 3) Loo-Riegelman (2-compartment model)
- 4) Loo-Riegelman (3-compartment model)
- 5) Wagner-Nelson (1-compartment model)

The Mechanistic Absorption Model (GastroPlus) deconvolution method directly deconvolutes the *in vivo* release rate. The other four methods are traditional deconvolution methods that calculate the rate of appearance of compound into the systemic circulation. For





formulation scientists, the correlation between in vitro release and in vivo release is much more intuitive and valuable.


Depending on the deconvolution method selected, a correlation can be made between *in vitro* release and *in vivo* release or *in vitro* release and absolute bioavailability. Currently, linear, power, and polynomial (second or third order) functions may be selected for the functional form of the correlation.

Run Convolutions: The correlation function can be used to calculate an *in vivo* release-time profile or absolute bioavailability-time profile for a new formulation of the compound exhibiting a different *in vitro* release-time profile. A plasma concentration-time profile for the new formulation can be constructed with the calculated *in vivo* release-time or absolute bioavailability-time profile.

Evaluate Validation Statistics: After running a convolution, IVIVCPlus outputs the observed values, predicted values, prediction errors, and mean absolute percent prediction error for both Cmax and AUC. These statistics can be used to evaluate the internal or external predictability of the correlation as described in the FDA's "Guidance for Industry Extended Release Oral Dosage Forms: Development, Evaluation, and Application of *In Vitro/In Vivo* Correlations".


PKPlus extends GastroPlus to rapidly estimate pharmacokinetic (PK) parameters for non-compartmental analysis (NCA), along with 1-, 2-, & 3-compartment models from IV and oral plasma concentration-time (Cp-time) data, without the need to run full simulations. The fitted parameters include PK parameters, first order absorption rate, bioavailability and absorption lag time (if both IV and oral data are included in fitting). Required inputs are Cp-time profiles, dose, body weight and infusion time (if applicable). Compartmental PK can be fitted to single IV or oral data as well as across multiple Cp-time profiles - IV, oral, or combination of IV and oral as well as different dose levels. Linear or saturable clearance models can be selected easily.

Full statistics, including Akaike Information Criterion and R², are provided for all models. Residual information is also captured and can be plotted. Once finished in PKPlus, the parameter values of the selected model can be easily transferred back to the main GastroPlus model, and all model results can be saved into report-guality outputs.



PKPlus(tm) Compartmental Pharmacokinetics File Model Options Search Method Objective Fu on Weighting O Plot Model O <u>1</u> Comp Edit Dosing Information Exit ● 2 Comp ○ 3 Comp 🥝 🐎 🔍 🛄 🛥 🔟 🚑 🐻 🖬 TWO-COMPARTMENT SIMULATION LINEAR MODEL 130 -120 110 I A 21.59 57.87 9.259 55.30 0.299 0.801 0.128 0.765 58.462 100 Ľ/h Concentration (ng/mL) 90 80 70 L L/h/kg L/kg L/h/kg L/kg /kg= 60 50 40 30 20 10 0.373 0.160 0.167 1/h 1/h 1/h 0.0522 15 Time (hrs Solve for compartment Plot Type **X** 1 **X** 2 **X** 3 Solve Absolute O Log O Residu

2-compartment model for midazolam fitted across IV and three oral doses



Residuals plot for 2-compartment model for midazolam fitted across IV and three oral doses

10

Plotting of absolute, log, and residuals for each model is selected with a mouse click, allowing rapid comparison of models.

Enhanced! Automated model selection – fit across all direct and indirect models, along with phase-nonspecific cell killing options, with a single mouse click!

PDPlus allows you to fit standard pharmacodynamic (PD) models to observed data and use the fitted models to predict PD effect changes due to changes in dose, dosage form, and dosing regimens. The PDPlus module adds the Pharmacodynamics Table, which contains the PD model, the site of PD action, and the parameters that determine the kinetics of the action. Multiple PD models (therapeutic and adverse) can be accommodated for each drug record.

Updated! Easily fit PD models across multiple data sets (e.g, doses)


With PDPlus, fitting pharmacodynamic models to observed effect data is quick and easy. You may fit any of the standard PD models:

Direct Link: Linear, Log Linear, Emax and Sigmoid Emax

Indirect Link: Class 1, Class 2, Class 3, Class 4

Other: Phase-nonspecific cell killing (for tumor PBPK/PD modeling)

Convenient plotting of both plasma concentration-time and effect vs. time or concentration is provided with absolute and log plots available for each. Plus, all model results can be saved into report-quality outputs.



The effect can be linked directly to drug concentration in a specific tissue to easily perform PBPK/PD modeling.

The Optimization Module for GastroPlus extends and enhances the program's basic capabilities in several important ways:

- To automatically fit model parameters to data
- To optimize study designs (e.g., dosing regimens) and dose

Fitting models to data

12

One of the most important uses of GastroPlus is to fit absorption, pharmacokinetic, and pharmacodynamic models to observations. In doing so, researchers gain tremendous insight into how their compound is behaving *in vivo*. When a single set of model parameters can be found that properly describes the observed plasma concentration-time for all dose levels, a useful model has been obtained. In general, if the model parameters must be changed for each dose level, then something is not being accounted for correctly. The Optimization Module performs the multidimensional search needed to fit model parameters to one or more data sets automatically.


Model fitting can include (but is not limited to):

- PBPK model parameters to plasma and/or tissue concentration vs. time data
- Peff and absorption scale factors to determine regional dependencies
- A wide variety of physiological parameters (when necessary)
- Parameters to match profiles of parent drugs or any of their metabolites

Model parameters can be fitted to data for a single record, or across multiple records simultaneously. The program will run one simulation for each record each time it changes the value(s) of one or more model parameters. Typically, hundreds of iterations will be performed, each with N simulations, where N is the number of records whose observations are being used to compare predicted and observed values. Objective function weighting is user-defined, and includes the most common weighting schemes.

ompound: Prop	vanolol HCI	Match Predicted to Observed Values for © Selected Record C Al Records				
		ſ	Total Parameters Selected = 0			
Pharmacokin ACAT	etics	mpound	Compound	Exemulation		
	Oral Cavity	Volume	Trans. Time			
	T Saliva Prod Rate	T %Fluid-Sma	Int Sendirs Tra Concurr Tra Color Trans	Ter		
	,			Next Finishe		

Objective Function We	ights	
C Unity	I/Yhat^2	Advanced Options
C 1/Y	C 1/(Y+Yhal)	
C 1/Y^2	1/(Y+Yhat)^2	
C 1/Yhat	C 1/Variance	
Compound: Proprar	olol HCI 💌	
Observation Weights f	or Selected Compound	
Fa OBJ Wei	ght: 🛛	
Fb OBJ Wei	ght: 0	
<u>T</u> Max OBJ Wei	ght: 0	
<u>C</u> Max OBJ Wei	ght: 0	
AUC OBJ Wei	ght: 0	
Conc-time OBJ Wein	ght: 1	
Therap Window Weig	aht: U	
Peak: 0	C After First Dose	
Trough: 0	C At Time 0	
support In.	a low strike for	
Next	Back Einished	




Each organ in the PBPK model is divided into three major compartments representing the vascular, endosomal, and interstitial spaces, as shown in the image at right.

NEW! PBPK models for antibody-drug conjugates (ADCs)

Starting in GastroPlus 9.0, we are pleased to offer PBPK models for large molecules (biologics). The Biologics Module simulates the absorption, distribution, and clearance of biological drugs. In the current implementation, both monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs) administered as an intravenous bolus dose, intravenous infusion, or subcutaneous (SQ) injection can be modeled. As with other GastroPlus modules, there is no equation or code writing required. A schematic diagram of how the different organs are connected to one another is shown at left.

All major organs are connected in an anatomical fashion with plasma flow represented by blue solid arrows and lymph flow by red dashed arrows. The lymph node collects the lymphatic drainage from organs and lymph fluid is returned to the systemic circulation. Each organ in the PBPK model is divided into three major compartments representing the vascular, endosomal, and interstitial spaces, as shown below.



Some of the key processes accounted for in the GastroPlus models include:

- Convective transport and fluid phase endocytosis describing uptake of antibody into the tissue
- mAb-FcRn (neonatal FC receptor) binding & recycling
- Target mediated elimination in the interstitial space to include the influence of specific antigen-mAb interactions on mAb disposition
- Within the endosomal space, the competition for binding to FcRn between endogenous IgG and the therapeutic mAb
- mAb administration by either intravenous (IV) or subcutaneous (SQ) injection
- Complete default physiology parameters for humans flexibility to create custom species models
- With ADCs, distribution and elimination processes of multiple ADC species with different DAR (drug-to-antibody ratio): o Distribute to peripheral compartments
 - o Cleared by nonspecific clearance
 - o Bind to target receptor, internalize, and be cleared in the cell lysosome



Results Part I: Overall performance on ITZ-MDZ drug-drug interaction

Table 2 summarizes the literature data on drug-drug interaction between IT2 and MDI [59]. The first time studies used obtained obsage forms while the rest used capule dosage forms of IT2. The demographic information and study portocol are also provided in the same table. On the day of MID administration, we assumed the subjects were in fed state for 3 hours after lunch and then writched to frasted state. Since both MID and IT2 are sensitive to prandial states, it is important to specify the physiological changes according to the meal schedule in the DDI simulations.

2 mg taken 4 hours after the inhibitor dose

n=6 (5:1); age 22-42 yrs

Didn't mention,

4 200 mg SD

200 mg SD 7.5 mg po taken 2 hours after the inhibitor dose on day 1 n=12 (7:5); age 19-25 yrs; weight 57-95 kg

for 3 hours.

3 400 mg SD

2 mg taken 4 hours after the inhibitor dose

n+6 (5:1); age 22-42 yrs

Didn't mention,

W5237

Mechanistic Absorption and Physiologically Based Pharmacokinetic Modeling of Itraconazole and Its Application for Drug-Drug Interaction with Midazolam in Adult Populations Ke X. Szeto, Viera Lukacova, John DiBella, Walter S. Woltosz, and Michael B. Bolger

Simulations Plus, Inc., 42505 10th Street West, Lancaster, CA 93534, USA

Table 2 su

Table 2. DDI study design details

 Trial No.
 1
 2

 ITZ
 50 mg SD
 200 mg SD

2 mg taken 4 hours after the inhibitor dose

n=6 (5:1); age 22-42 yrs

Study Protocol Didn't mention,

Parcere (A)

T D D T D D T

F

1

Figure 1: M administrati condition. B remaining 1 entering sys-

-

TALLER .

Emulation Time (N)

Figure 2: Mean simulated (line) and observed (points) pnarmacos...... administration of 200 mg ITZ to a 23-year-old male of 70.9 Kg under condition. The color-coded lines follow the same definition as in Figure 1.

1111

Contension (April)

(S) and

Annual Section Terror Data

American Terra da

MAK

ed (left) and fed (right) (y-axis on the left). The

Introduction Itancen Pharmacoulic, Ticuvile, NJ, R is a substrate and potent individual of the substrate and potent individual of the substrate and potent individual of the two other downstraam metabolics, letio-tracensorie (letical 2nd 4-desity)-Itancanosia (No-IT2), are also substrates and inhibitors of CYP3A. The purpose was to develop a metabolities, which accounts for all the relevant mechanism metabolities, which accounts for all the relevant mechanism auto-inhibition of CYP3A. The purpose was to develop a disolution, precipitation, absorption, distribution, metabolism, and auto-inhibition) after i.v. and p.o. IT2 administration. This model was validated by predicting effect of IT2 administration on midazolam (MD) pharmacolinetic (PK).

Introduction

METHODS NETHODS The PBPKPusth module in Gastrolive'' (Simulations Plus, Inc.) was used to model the PK of 172 and the three metabolites. The Advanced Comparimental Absorption and Trasit (ACMth) model was used to describe the intestinal dissolution, precipitation, and absorption of 172 after p.o. administration. Human physiologies were generated by the program's internal Population Estimates for Age-Neisted (PAK-197) Physiologyth model. Tissue/plasma partition coefficients for all the compounds were calculated using the Lukacova algorithm based on tissue composition and in wire and in alico physicochemical properties. The biopharmiceatucal from literature or pedicided by ADMIP Predictor¹⁶ (Simulations Plus, Inc.). The metabolism series from 172 to 0H-172 to Interdicted by the CP4744 enzyme) was modeled by the CP44 enzyme). Plus, Inc.). The metabolism series from 172 to 04-172 to keto-172 with No1-172 (all mediated by the C/1924 enzyme) was modelled by Michaelis-Menten kinetics with *in vitro* enzyme kinetic parameters and the GastroPlus built-in expression levels of C/1924 with ing with and liver. The default dissolution model was used for both solution and adjusted to 3 µm to account for the capsule dosage form was adjusted to 3 µm to account of the the capsule dosage form segregaris' mechaniskis runcleation and growth (MMG) model was used to account for possible precipitation as 112 solubility changes in different intestinal regions. The permeability of 112 was predicted in MemioanePlus[®] 1.0 (Simulations Plus, Inc). The DDI module les GastroPlus was used to predict the effect of 112 on MID PF for a variety of study administration time

	Ki,u (nM)	Km,u (nM)
ITZ	1.3	3.9
OH-ITZ	14.4	27
Keto-ITZ	1.4*	1.4
ND-ITZ	0.38#	0.38


Notifield whether his holds the threshold entrymely was modelled by Michaelis Mention kinetic parameters with a with a micro magnetization that the second	The second secon		Titul No. 5 6 7 17. 200 mg QD for 100 mg QD for 1200 mg L for 1200 mg QD f	210 52 cm g20 for 4 days 320 mg 00 for 4 days 0 15 mg taken 2 7.5 mg po taken 1 hoar the inhibitor doce on days 0 15 mg taken 2 7.5 mg po taken 1 hoar the inhibitor doce on days 0 15 mg taken 2 7.5 mg po endet 0 15 mg taken 2 7.5 mg po endet 10 16 mg taken 2 7.5 mg po endet 10 16 mg taken 2 7.5 mg po endet 10 16 mg taken 2 7.5 mg po endet 10 19 mg taken 2 19 mg taken 2 10 19 mg taken 2 19 mg taken 2 10 19 mg taken 2 19 mg taken 2 10 19 mg taken 2 19 mg taken 2 10 19 mg taken 2 19 mg taken 2 10 19 mg taken 2 19 mg taken 2 10 19 mg taken 2 19 mg taken 2 10 19 mg taken 2 19 mg taken 2 10 19 mg taken 2 19 mg taken 2 10 19 mg taken 2 19 mg taken 2 10 19 mg taken 2 19 mg taken 2 10	The work demonstra approach to predict (but its multiple meta MAM/PBPK approach absorption, distributic prediction of PK for Including all the major for accurate predict presented in Figure 5	DDI interactions im abolites (and meta h incorporates all on, metabolism, an r different dosage ir downstream meta tion of the DDI show that the mod	the GastroPlus MAM/PBPK wolving not only perpetrator, abolites of metabolites). The relevant processes in drug delimination and helps with e forms and study designs. tabolites of ITZ was important effect. The overall results del predicts accurately across
OH-TIZ 14.4 27 Keto-HIZ 1.4* 1.4 NO-TIZ 0.38 0.38 "Alu the term in Nu 0.38 0.38 "Mount of the modulation (CMD) and in the incubed MEZ surveithering 1.00 (CMD) and incubed	For the second s	للمعلم المعلم المعلم المعلم المعلم المعلم المعلم المعلم الم المعلم المعلم الم	tic (PBPK) mode kinetics in childl W.S. Woltosz, M.B. Bo	I for predic	precipitation model. GastroPlus MAM/ physicochemical proc valuable and reliable p	To conclude, (PBPK approach cesses and physio predictive utility. MULAT	expande does uning the MNG we have show that the h, integrating relevant biological details, is a highly biomsPluss WARE = SUCCESS
Simulations Plus	s, Inc. Lancast		rrespondence should be ad	-	@simulations	-plus.com	
<text><section-header><section-header><section-header><section-header><text></text></section-header></section-header></section-header></section-header></text>	The PBFK volume) as the product on the relation of the relati	apinst the observed Cp-line profile aft by predicting VOH plasma and kifes into (Figure 1). The model developed in VOH PK in adult humans (Figure 2) in children in, miclufing neonates and m hysiologies, was also able to predict th hysiologies, was also able to predict th <i>IV bolus Smpk ral</i> <u>Bioudation Time (h)</u> able of the size	Human IV inf 1000mg - predicted from rat Under the second	<text><text><figure></figure></text></text>	Arrow of the second sec	The second secon	a) der L: varianisation activité autoristance settament a mol (3) Standalessa uit le satisficación (4) Standalessa uit le satisficación (4) Standalessa physiological changes in the the FK of VCN in neonates esta and FNA2 days to 20 0. VCN FK after 15 mgAg (1). Cucitade from dolessa and Al by considering the standalessa and fNA2 days to 20 0. UCN FK after 15 mgAg (1). PGFK fronted Fasalitation (4) by considering the standalessa and fNA2 days to 20 or normal and FNA1 and 10 standalessa molecular days and about the standalessa and the standalessa and molecular days and the standalessa and standalessa and standalessa and standalessa and standalessa and FR with after forestang papely and standalessa and standalessa and FR with after forestang papely and standalessa and standalessa and FR with after forestang papely and standalessa and standalessa and fil -34 webs (1), and standalessa and standalessa and standalessa and fil -34 webs (1), and standalessa and standalessa and fil and standalessa and standalessa and fil and standalessa and fil -34 webs (1), and standalessa and fil -34 webs (1), and standalessa and standalessa and standalessa and fil -34 webs (1), and standalessa and standalessa and standa

11 4 5 Trial Number

Figure 5: Predicted (blue) and observed (green) fold changes in AUC ratios for midazolam under ITZ inhibition effect. Note that study 9 has been corrected for gender effect on


Cr32A legences text Part I: DDI Contribution from TZ and its metabolites Lastly, in this section, we discuss the individual contribution of ITZ and its metabolites to the overall DDI effect. Here we simulated the inhibition effect of 100mg TZ on oral MDI tables (7.5 mg) 4 days after the versament. Table 3 summarizes the predicted AUC racios under different model settings: 4 competitive substrates (172, hydroxyHTZ, substrates (172, hydroxyHTZ) and 1 substrates (1172, hydroxyHTZ), substrates (1172, hydroxyHTZ) and 1 substrates (1172, hydroxyHTZ) as us there are ontributed a summarizes using of AUC and ND-TZ was the main contributor as among ITZ and its metabolites. Tols result is consistent with data publiced in literature suggesting that ND-TZ was the most potent inhibitor in associated with the metabolites [102], and that 50% of inhibition is associated with the metabolites [102], and that 50% of

inhibition is associated with the metabolites of ITZ [5]. Table 3. DDI contribution from ITZ and its metabolites.								
	ITZ model (number of subs)	4	3	2	1	Obs Values ^{[6}		
	AUC_competitive (ng-h/mL)	433.10	303.60	269.30	244.50	586		





For copies of any posters, please contact us at info@simulations-plus.com



- The validated final model, which was extended to predict the effects of liver impairment by incorporating physiological changes associated with different degrees of seventy of liver cirrhosis (Figure 2), agreed reasonably well with observed data from patients with compensated and decompensated hepatic impairment (Figure 3).
- Decrease in hematocrit
 Decrease in plasma proteins ai
 Decrease functional liver mass
 Decrease GFR Decrease hepatic enzymatic activity

15

Level A IVIVC Using a Comprehensive Absorption/PBPK Model for Metoprolol

John I. Chung, Viera Lukacova, John R. Crison, Michael B. Bolger, & Walter S. Woltosz

Simulations Plus, Inc. 42505 10th Street West, Lancaster, CA 93534



Wagner-Nelson, Los-Riegelman, numerical deconvolution, and convolution-based methods are conventional ways to form an in viro-in viro- correlation (UVC). The chimate goal for forming an UVC is to declosely a correlation or relationship between the river relates and a rive relates of a formulation so that an *in viro* release profile can be predicted from a given in viror relates profile. The Wagner Nelson and Los Keigelmon methods form a correlation between *in viror* relates and howavailability, which is not truly argumentative of a correlation of factors such as an viror relates and howavailability is discussibility in affected by a combination of factors such as an viror relates and howavailability is discussibility of an effected by a combination of factors such as an viror relates and howavailability declosed and convolution-based methods can be used to develop a correlation between *in viron* relates and *all* viror factors. Such as assumption of linear kinetics, which may not be appropriate for drugs that exhibit nonlinear planmacokinetics.

Physiologically based pharmacokinetic (PBPK) models offer an alternative approach in which a Physiologically based plasmacokieric (PBPA) models offer an alternative approach in which a direct correlation between in vitro release and a rivo release and models and the second second direct correlation between its vitro discase and a rivor datase data regimes and correlation between basevailability and in vitro datase ottamic mechanistic models that better represent the absorption, distribution, metabolism and excertion processes coursing in vitro than empirical model that lamps these processes into out, two or these comparisons. These administrations are the relevant of the second second second second second second second second administer second relevance and a to calcular plasmacchinet (CK) parameters. These administer second relevance and a tracking method to form a TVVC.

Metoproloi is a widely used beta, selective blocking agent indicated for treatment of hypert angina pectoris and stable, symptomatic heart failure [1]. Under the Biophama Classification System (BCS), it is classified as a Class I compound. Metoproloi is a weak ba a pka of 92.12] and is metabolized predominantly by CYP2D5[1].

Objective

Form a Level A IVIVC using a comprehensive absorption/PBPK model for metoprolol.


Methods

⁴ Construct a comprehensive metopolol absorption/PBPK model for a typical 30 year old male [3] using the PBPK/Burk¹⁰ model in Gastro²Burk¹⁰ (Simulations Plus, Inc.). Estimate tissue plasma plantino coefficients (Kp) using a modification of a metod described by Rodgres and Rowlad [4]. Use *in vitro* metabolic measurements in human liver and intestinal microsomes as estimates for metabolic classification of a study described by Rodgres and Rowlad [4]. Since in vitro metabolic measurements in human liver and intestinal microsomes as estimates for metabolic classification of a metod described by Rodgres and the single and described by Rodgres and the single model using plasma concentration-time data obtained by higtoria entreprotocid solution directly in the legistrum and douto [6].

Obtain in vitro dissolution-time and plasma concentration-time profiles for three hydrophilic 100
mg metoprolot tartrate extended release (ER) tablet formulations (fast, moderate, slow) from the
literature [7, 8].

2980

"Form an UVCC by fitting a single best average polynomial to the two resulting *in vrov* vs. in stror release currents.
"Convolute all three formulations (dow, moderate, & fast) using the fitted polynomial VC the two same two high-polynomial (the polynomial data test ER table from ulations to form 1VVC with the Low-Regelman method (plannacoldurine parameters for 2 comparison VVC with the Low-Regelman method (plannacoldurine parameters) for 2 comparison VVC with the Low-Regelman method (plannacoldurine parameters) for 2 comparison VVC with the Low-Regelman method (plannacoldurine parameters) for 2 comparison VVC with the Low-Regelman method (plannacoldurine parameters) for 2 comparison VC with the site of th



(a)

(b)

Application of PBPK Modeling to Predict Monoclonal Antibody Disposition after Intravenous and Subcutaneous Administration in Rats and Humans

Haiying Zhou, Michael B. Bolger, Viera Lukacova


Simulations Plus, Inc., 42505 10th Street West, Lancaster, CA 93534, USA

PURPOSE

Therapeutic monocional antibodies (mAbs) represent a growing segment of the development pipeline in the pharmaceutical industry. Physiologically based pharmacokinetic (PBPK) modeling has been extensively applied in small molecule drug development and has a great potential of heiping in the development of mAbs and functional deviatives. In this study, a comprehensive PBPK model for mAbs was developed to simulate plasma as well as individual tissue concentrations after intravenous (IV) or subcutaneous (SC) administration in preclinical animals and humans. als and hum

METHODS





The following mechanisms are included in the PBPK mode he following mechanisms are included in the PBPK model: Transport of mak hinto the tissue interstitial space via convective flow through the paracellular pores in the vascular and interstitial spaces via the uptake of mAb from the vascular and interstitial spaces into the endosomal space via fluid-phase endocytosis pH-dependent binding of mAb to FRA in the endosomal space FRA binding competition between therapeutic mAb and endogenous via


- lgG Recycling of mAb to the vascular and interstitial spaces
- Endosomal degradation of the unbound mAb
- Return of mAb from the tissue to the bloodstream through convective transport with lymph flow
- · Specific mAb binding to antigen (TMDD)

After SC injection, the mAb was initially distributed in the interstitial space of the local subcutaneous tissue. The local tissue was also divided into three compartments as shown in Figure 1. The same endosomal nonspecific clearance processes were applied to both the systemic clearance and local fint-space sclearance after SC administration.

clearance and local first-pass clearance after SC administration. Convective transport through the lymphatic and huid-phase endocytosis are the main mechanisms of absorption into the systemic circulation following SC administration of mAb. The vascular (G) and lymph (g) reflection coefficients, and the fraction of mAb recycled (FR) were obtained from literature (Garg & Balthasar, J Pharmacokinet Pharmacotyn, 34 (2007), 687-709). Other model parameters (pt-dependent mAb-FGR huiding constants, mAb degradation in endosomal space, endosomal uptake, and recycle rates) were fitted synthesis rate of endogenous IgG (Junghans, Blood, 90 (1997), 3815-3816; Cure & Cremer, J Immunol, 102 (1996), 1345-1353) of different species. The fitted mAb-FGR huiding constants were within the range of reported in vitro values (Datt-Mannan et al., J Biol Chem, 282 (2007), 1709-1717; Andersen et al., J Biol Chem, 285 (2010) 4826-4836).

RESULTS

The PBPK model for mAbs was used to simulate plasma concentration The POPK induction indus was used to similate passing concentration-time profiles of MEDi-528 in human and Ritkimab in rats across different dose levels after IV and SC administration. The simulated profiles were in close agreement with published cilicial results (White et al., Clin Ther, 31 (2009), 728-740; Kagan et al., Pharm Res, 29 (2012), 490-499). (a)



Default model parameters for human were used for MEDI-528 simulations





Figure 3: Comparison of simulated (lines) and measured (points) Rituximab for 1 and 10 mg/kg doses in Wistar rats after IV (a) and SC (b) doses

I and to highly duotes in invalue in a late in Vig. and oc. (b) doese The association coefficient between Ritkumina and and aff-CRn was estimated using the data from the 1 mg/kg IV does. For the simulation of Ritkuminab in rask after SC administration, an additional linear clearance was included in the local frist-pass clearance in addition to the endosomal nonspectic clearance processes and was estimated using the data from the 1 mg/kg SC does. Other parameters used the default GastroPlus values for rat.



CONCLUSIONS

- PBPK modeling of mAbs in GastroPlus accurately simulates PK profiles after IV and SC administration.
 This model can help to investigate the factors responsible for the systemic disposition of mAbs in preclinical animals and human.
 This model could also be applied to assess dose-dependent nonlinear clearance related to TMDD



Revised 1/24/17

